DLL3 Targeting CAR-T Cell Therapy Patent Granted to Allogene Therapeutics
Summary
The USPTO granted Patent US12606623B2 to Allogene Therapeutics, Inc. covering DLL3 binding agents and chimeric antigen receptors (CARs) for use in immune cell therapies, specifically CAR-T cells. The patent includes 26 claims and covers methods of making and using DLL3-specific CARs. This grant establishes exclusive IP rights for the assignee in the specified therapeutic domain.
What changed
USPTO issued Patent US12606623B2 to Allogene Therapeutics, Inc. covering DLL3 targeting chimeric antigen receptors and binding agents for CAR-T cell therapy. The patent includes 26 claims spanning multiple CPC classifications including C07K 16/28, C07K 14/705, and A61P 35/00 (cancer therapeutics).
Pharmaceutical and biotechnology companies developing CAR-T or other DLL3-targeted cell therapies should review this patent to assess potential freedom-to-operate implications. Licensees or collaborators of Allogene should confirm the scope of coverage aligns with existing agreements.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DLL3 targeting chimeric antigen receptors and binding agents
Grant US12606623B2 Kind: B2 Apr 21, 2026
Assignee
ALLOGENE THERAPEUTICS, INC.
Inventors
Yi Zhang, Thomas John Van Blarcom, Siler Panowski, Silvia K. Tacheva-Grigorova, Barbra Johnson Sasu
Abstract
Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.
CPC Classifications
C07K 16/2809 C07K 16/2887 C07K 2317/24 C07K 2317/565 C07K 2317/622 C07K 2319/70 C07K 2319/03 C07K 2319/33 C07K 16/28 C07K 14/705 C07K 14/7051 C07K 14/70578 C07K 14/70596 C07K 16/18 A61K 40/11 A61K 40/31 A61K 40/4202 A61K 40/4204 A61K 2039/505 A61K 2239/31 A61K 2239/38 A61K 2239/55 A61K 2121/00 A61K 2300/00 A61K 40/42 A61P 35/00 C12N 5/0636 C12N 15/63 C12N 2510/00
Filing Date
2023-04-27
Application No.
18308143
Claims
26
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.